Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

Abstract

BackgroundVCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed to find the maximum tolerated dose/recommended phase II dose (RP2D) and dose-limiting toxicity (DLT) of the intravenous delivery of the replication-competent VCN-01 adenovirus in patients with advanced cancer.MethodsPart I: patients with advanced refractory solid tumors received one single dose of VCN-01. Parts II and III: patients with pancreatic adenocarcinoma received VCN-01 (only in cycle 1) and nab-paclitaxel plus gemcitabine (VCN-concurrent on day 1 in Part II, and 7 days before chemotherapy in Part III). Patients were required to have anti-Ad5 neutralizing antibody (NAbs) titers lower than 1/350 dilution. Pharmacokinetic and pharmacodynamic analyses were performed.Results26% of the patients initially screened were excluded based on high NAbs levels. Sixteen and 12 patients were enrolled in Part I and II, respectively: RP2D were 1×1013 viral particles (vp)/patient (Part I), and 3.3×1012 vp/patient (Part II). Fourteen patients were included in Part III: there were no DLTs and the RP2D was 1×1013 vp/patient. Observed DLTs were grade 4 aspartate aminotransferase increase in one patient (Part I, 1×1013 vp), grade 4 febrile neutropenia in one patient and grade 5 thrombocytopenia plus enterocolitis in another patient (Part II, 1×1013 vp). In patients with pancreatic adenocarcinoma overall response rate were 50% (Part II) and 50% (Part III). VCN-01 viral genomes were detected in tumor tissue in five out of six biopsies (day 8). A second viral plasmatic peak and increased hyaluronidase serum levels suggested replication after intravenous injection in all patients. Increased levels of immune biomarkers (interferon-γ, soluble lymphocyte activation gene-3, interleukin (IL)-6, IL-10) were found after VCN-01 administration.ConclusionsTreatment with VCN-01 is feasible and has an acceptable safety. Encouraging biological and clinical activity was observed when administered in combination with nab-paclitaxel plus gemcitabine to patients with pancreatic adenocarcinoma.Trial registration numberNCT02045602.

Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders

“…High levels of pre-existing antibodies will interfere with transduction efficacy and impair transgene delivery to the target tissues [ 9 , 70 ]. Some gene therapy and oncolytic virus therapy trials have specified exclusion criteria with regard to HAdV neutralizing antibodies and excluded patients with HAdV-neutralizing antibody titers ranging from 1:320 to 1:1000 [ 71 , 72 , 73 , 74 ]. Our data show that for some species A, B, and D HAdV types, all serum donors in our study would be below such exclusion titers, confirming these types as promising candidates that are worth pursuing.…”

Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic

“…Because of the impact of anti-HAdV immunity on the efficacy of HAdV-based vectors, clinical trials often include HAdV preimmunity-specific exclusion criteria. While many gene therapy or oncolytic vector trials exclude participants who were previously treated with HAdV-based vectors ( 14 – 19 ), others specified anti-HAdV neutralizing antibody (nAb) titers ranging from 1:320 to 1:1,000 as exclusion criteria ( 20 – 23 ). In HAdV-based vaccine studies, subjects have often been stratified according to their anti-HAdV neutralizing antibody titers, with neutralizing antibody titers of up to 1:45 ( 24 ) or 1:200 being regarded as low ( 7 , 11 , 12 , 25 ).…”

Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment

“…The vector was modified with a transgene encoding the integrin-binding RGDK motif, inserted in the fiber domain, and a sequence encoding human recombinant hyaluronidase. Deletion in the E1A gene ensured selectivity of replication in cancer cells only [ 125 ]. CG0070 is also an interesting vector that entered phase III clinical trials in in 2022.…”